Systemic treatment in advanced melanoma [Systemische behandlung beim fortgeschrittenen melanom]

[1] Ryan L., Kramar A., Borden E., Prognostic factors in metastatic melanoma, Cancer, 71, (1993)

[2] Comis R., DTIC (NSC-45388) in malignant melanoma: A perspective, Cancer Treat Rep, 64, (1976)

[3] Balch C., Soong S., Murad T., Smith J., Maddox W., Durant J., A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III), J Clin Oncol, 1, pp. 126-134, (1983)

[4] Ahman D., Creagan E., Hahn R., Edmonson J., Bisel H., Schaid D., Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma, Cancer, 3, pp. 224-227, (1989)

[5] Middleton M., Gore M., Tilgen W., Fierlbeck G., Grob J., Coates A., Et al., A randomized phase III study of temozolamide (TMZ) versus dacarbazine (DTIC) in the treatment of patients with advanced metastatic melanoma, (1999)

[6] Al-Sarraf M., Fletcher W., Oishi N., Pugh R., Hewlett J.S., Balducci L., Et al., Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A southwest oncology group study, Cancer Treat Rep, 66, pp. 31-35, (1982)

[7] Mechl Z., Krejci P., Cis-diamminedichloroplatinum in the treatment of disseminated malignant melanoma, Neoplasma, 30, 3, pp. 371-377, (1983)

[8] Rosenthal M.A., Bull C.A., Coates A.S., Stevens G., McCarthy W.H., Mameghan H., Et al., Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma, Eur J Cancer, 27, pp. 1564-1566, (1991)

[9] Casper E.S., Bajorin D., Phase II trial of carboplatin in patients with advanced melanoma, Invest New Drugs, 8, pp. 187-190, (1990)

[10] Glover D., Glick J.H., Weiler C., Fox K., Guerry D., WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma, J Clin Oncol, 5, pp. 574-578, (1987)

[1] Ryan L., Kramar A., Borden E., Prognostic factors in metastatic melanoma, Cancer, 71, (1993)

[2] Comis R., DTIC (NSC-45388) in malignant melanoma: A perspective, Cancer Treat Rep, 64, (1976)

[3] Balch C., Soong S., Murad T., Smith J., Maddox W., Durant J., A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III), J Clin Oncol, 1, pp. 126-134, (1983)

[4] Ahman D., Creagan E., Hahn R., Edmonson J., Bisel H., Schaid D., Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma, Cancer, 3, pp. 224-227, (1989)

[5] Middleton M., Gore M., Tilgen W., Fierlbeck G., Grob J., Coates A., Et al., A randomized phase III study of temozolamide (TMZ) versus dacarbazine (DTIC) in the treatment of patients with advanced metastatic melanoma, (1999)

[6] Al-Sarraf M., Fletcher W., Oishi N., Pugh R., Hewlett J.S., Balducci L., Et al., Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A southwest oncology group study, Cancer Treat Rep, 66, pp. 31-35, (1982)

[7] Mechl Z., Krejci P., Cis-diamminedichloroplatinum in the treatment of disseminated malignant melanoma, Neoplasma, 30, 3, pp. 371-377, (1983)

[8] Rosenthal M.A., Bull C.A., Coates A.S., Stevens G., McCarthy W.H., Mameghan H., Et al., Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma, Eur J Cancer, 27, pp. 1564-1566, (1991)

[9] Casper E.S., Bajorin D., Phase II trial of carboplatin in patients with advanced melanoma, Invest New Drugs, 8, pp. 187-190, (1990)

[10] Glover D., Glick J.H., Weiler C., Fox K., Guerry D., WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma, J Clin Oncol, 5, pp. 574-578, (1987)